Hirtle Callaghan & Co LLC Takes Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Hirtle Callaghan & Co LLC has purchased 2,000 shares of Thermo Fisher Scientific Inc. for approximately $995,000, indicating growing interest in the company from institutional investors.
• Thermo Fisher reported quarterly earnings of $5.36 per share, surpassing analysts' expectations, with a revenue of $10.86 billion for the quarter.
• The company recently announced a quarterly dividend of $0.43, with a yield of 0.4% and a low dividend payout ratio of 9.95%.

Hirtle Callaghan & Co LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 2,000 shares of the medical research company's stock, valued at approximately $995,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cypress Advisory Group LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $253,000. GAMMA Investing LLC lifted its position in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock worth $2,419,000 after buying an additional 877 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock worth $687,553,000 after buying an additional 114,277 shares during the last quarter. Hancock Whitney Corp lifted its position in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock worth $2,802,000 after buying an additional 30 shares during the last quarter. Finally, Cetera Trust Company N.A lifted its position in shares of Thermo Fisher Scientific by 3.3% during the 1st quarter. Cetera Trust Company N.A now owns 4,646 shares of the medical research company's stock worth $2,312,000 after buying an additional 150 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 8,000 shares of the stock in a transaction dated Thursday, August 7th. The stock was sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $52,340,824.30. The trade was a 6.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 over the last ninety days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO traded up $6.60 during trading hours on Friday, reaching $461.34. The company's stock had a trading volume of 1,689,914 shares, compared to its average volume of 3,227,669. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The company's 50-day moving average is $426.80 and its two-hundred day moving average is $463.40. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The stock has a market cap of $174.21 billion, a PE ratio of 26.68, a PEG ratio of 2.46 and a beta of 0.74.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. During the same period last year, the company posted $5.37 EPS. The company's revenue was up 2.9% on a year-over-year basis. Analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Wall Street Analyst Weigh In

Several analysts recently commented on the stock. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a research report on Thursday, April 24th. Barclays upped their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Royal Bank Of Canada reduced their price target on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating for the company in a research report on Thursday, April 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, Evercore ISI reduced their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research report on Tuesday, July 8th. Seven equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.